Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The trial will be performed to evaluate whether BI 2536 may be effective in the treatment of
advanced or metastatic NSCLC of stage IIIB or IV in patients who relapsed after or failed
first-line therapy. A secondary aim is to identify the most suitable dosage schedule for the
further Phase II and III clinical programme of BI 2536. To achieve this objective two dosage
schedules are compared.